Labroots

HRD assessment using Oncomine Comprehensive Assay Plus

Dr. Elaine Wong-Ho will review homologous recombination deficiency (HRD) assessment with the Oncomine Comprehensive Assay Plus and review current HRD studies from leading experts in diagnostics. New ...
ascopubs.org

Clinical assessment of HRD scoring in relation to PARPi response in terms of statistical guidance on reporting results for CDx tests evaluation.

Overall survival in treated ovarian cancer patients in Argentina: OCEANIA study.
Labroots

Next-Generation Sequencing (NGS) Assessment of Homologous Recombination...

NGS tumor profiling has become the mainstay of modern cancer therapy. Several NCCN-guided and FDA-approved therapies are currently on-market targeted by tumor genotype, and research is ongoing to ...
ascopubs.org

High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency–Associated Genomic Instability in Ovarian Cancer

Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown promising clinical results in the treatment of ovarian cancer. Analysis of biomarker subgroups consistently revealed higher benefits for ...